America’s fragile drug supply chain is extremely vulnerable to climate change

The article discusses the vulnerability of America's drug supply chain to the impacts of climate change. It highlights that more than 60% of US drug facilities are located in areas prone to extreme weather events, such as hurricanes, floods, and wildfires. This raises concerns about the potential disruption to the production and distribution of essential medications. The article notes that the concentration of drug manufacturing and distribution in certain regions, coupled with the reliance on global supply chains, makes the system highly susceptible to the effects of climate change. Disruptions to transportation, power, and water supplies can lead to shortages and delays in the availability of critical drugs. The article suggests that this issue requires attention from policymakers and industry leaders to address the risks and build resilience in the drug supply chain. Strategies may include diversifying manufacturing locations, improving disaster preparedness, and investing in infrastructure to mitigate the impact of climate-related events.